$ADVM
Adverum Biotechnologies, Inc.

2016 Q1 Form 10-Q Financial Statement

#000156459016018295 Filed on May 06, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q1
Revenue $265.0K $203.0K
YoY Change 30.54% 576.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.320M $4.140M
YoY Change 100.97% 467.12%
% of Gross Profit
Research & Development $7.460M $5.621M
YoY Change 32.72% 517.69%
% of Gross Profit
Depreciation & Amortization $320.0K $120.0K
YoY Change 166.67% 1100.0%
% of Gross Profit
Operating Expenses $15.77M $9.764M
YoY Change 61.54% 496.82%
Operating Profit -$15.51M -$9.561M
YoY Change 62.2% 495.33%
Interest Expense $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $116.0K $52.00K
YoY Change 123.08% -191.23%
Pretax Income -$15.39M -$9.510M
YoY Change 61.83% 472.89%
Income Tax
% Of Pretax Income
Net Earnings -$15.39M -$9.509M
YoY Change 61.87% 471.8%
Net Earnings / Revenue -5808.3% -4684.24%
Basic Earnings Per Share
Diluted Earnings Per Share -$567.9K -$382.1K
COMMON SHARES
Basic Shares Outstanding 26.86M 25.22M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $247.1M $290.1M
YoY Change -14.82% 144950.0%
Cash & Equivalents $247.1M $201.8M
Short-Term Investments $0.00 $88.30M
Other Short-Term Assets $1.000M $1.000M
YoY Change 0.0% 150.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $249.2M $291.1M
YoY Change -14.4% 36291.5%
LONG-TERM ASSETS
Property, Plant & Equipment $3.600M $1.421M
YoY Change 153.34% 1321.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $138.0K
YoY Change -27.54% -31.0%
Total Long-Term Assets $3.734M $1.559M
YoY Change 139.51% 419.67%
TOTAL ASSETS
Total Short-Term Assets $249.2M $291.1M
Total Long-Term Assets $3.734M $1.559M
Total Assets $252.9M $292.7M
YoY Change -13.58% 26508.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $486.0K $2.787M
YoY Change -82.56% 209.67%
Accrued Expenses $3.900M $2.500M
YoY Change 56.0% 257.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.600M $7.628M
YoY Change -26.59% 376.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $5.800M $5.400M
YoY Change 7.41% 5300.0%
Total Long-Term Liabilities $5.800M $5.400M
YoY Change 7.41% 2600.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.600M $7.628M
Total Long-Term Liabilities $5.800M $5.400M
Total Liabilities $11.37M $13.01M
YoY Change -12.63% 622.83%
SHAREHOLDERS EQUITY
Retained Earnings -$99.56M -$46.22M
YoY Change 115.39%
Common Stock $341.1M $325.9M
YoY Change 4.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $241.6M $279.7M
YoY Change
Total Liabilities & Shareholders Equity $252.9M $292.7M
YoY Change -13.58% 26508.27%

Cashflow Statement

Concept 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$15.39M -$9.509M
YoY Change 61.87% 471.8%
Depreciation, Depletion And Amortization $320.0K $120.0K
YoY Change 166.67% 1100.0%
Cash From Operating Activities -$12.15M -$7.740M
YoY Change 56.98% 473.33%
INVESTING ACTIVITIES
Capital Expenditures $122.0K $411.0K
YoY Change -70.32% 774.47%
Acquisitions
YoY Change
Other Investing Activities $37.74M -$88.37M
YoY Change -142.71%
Cash From Investing Activities $37.62M -$88.78M
YoY Change -142.37% 177460.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.300M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 260.0K 139.0M
YoY Change -99.81% 13798.0%
NET CHANGE
Cash From Operating Activities -12.15M -7.740M
Cash From Investing Activities 37.62M -88.78M
Cash From Financing Activities 260.0K 139.0M
Net Change In Cash 25.73M 42.46M
YoY Change -39.4% -10715.0%
FREE CASH FLOW
Cash From Operating Activities -$12.15M -$7.740M
Capital Expenditures $122.0K $411.0K
Free Cash Flow -$12.27M -$8.151M
YoY Change 50.56% 483.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
140000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5621000
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
3000
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
341114000
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9000
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99560000
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
241566000
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
252934000
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2016Q1 us-gaap Assets
Assets
252934000
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
486000
CY2016Q1 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
49000
CY2016Q1 aavl Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
3889000
CY2015Q4 aavl Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
4007000
CY2016Q1 us-gaap Liabilities
Liabilities
11368000
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27094955
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27094955
CY2016Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
265000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
15773000
CY2015Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
449000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1463000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
260992000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3187000
CY2015Q1 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-1000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-140000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1771000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-676000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-764000
CY2016Q1 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-964000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
853000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
138975000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15508000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9561000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
116000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
52000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
116000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
52000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-15392000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-9509000
CY2016Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
6000
CY2015Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-35000
CY2016Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
14000
CY2015Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-8000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15372000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9552000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27095000
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24887000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
320000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
118000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4084000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
773000
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-59000
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
668000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-441000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
120000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-203000
CY2016Q1 us-gaap Straight Line Rent
StraightLineRent
11000
CY2015Q1 us-gaap Straight Line Rent
StraightLineRent
-134000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12153000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7742000
CY2015Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
88370000
CY2016Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
37738000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
122000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
411000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
37616000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-88781000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
138954000
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
262000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
262000
CY2016Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
9000
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-7000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
25734000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
42445000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159404000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
201849000
CY2016Q1 aavl Fixed Assets In Accounts Payable And Current Liabilities
FixedAssetsInAccountsPayableAndCurrentLiabilities
576000
CY2015Q1 aavl Fixed Assets In Accounts Payable And Current Liabilities
FixedAssetsInAccountsPayableAndCurrentLiabilities
278000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2016Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-07-17
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2369375
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
130600000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8300000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
230000
CY2016Q1 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
0
CY2016Q1 us-gaap Held To Maturity Securities Sold Security Realized Gain Loss
HeldToMaturitySecuritiesSoldSecurityRealizedGainLoss
0
CY2015Q4 aavl Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
208588000
CY2015Q4 aavl Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2015Q4 aavl Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
0
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
208588000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
37738000
CY2016Q1 us-gaap Maturities Of Time Deposits Description
MaturitiesOfTimeDepositsDescription
Less than one year
CY2016Q1 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2016Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2016Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
241663000
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
246320000
CY2016Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4876000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4178000
CY2016Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1311000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
991000
CY2016Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1077000
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2047000
CY2016Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1523000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1177000
CY2016Q1 aavl Accrued Preclinical Costs
AccruedPreclinicalCosts
731000
CY2015Q4 aavl Accrued Preclinical Costs
AccruedPreclinicalCosts
642000
CY2015Q4 aavl Accrued Clinical And Development Process Costs
AccruedClinicalAndDevelopmentProcessCosts
101000
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
558000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40000
CY2016Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
0
CY2016Q1 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0
CY2016Q1 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
0
CY2016Q1 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2015Q3 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
3
CY2016Q1 aavl Share Based Compensation Arrangement By Share Based Payment Award Options Difference Between Options Exercise Price And Closing Price Of Common Stock Intrinsic Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDifferenceBetweenOptionsExercisePriceAndClosingPriceOfCommonStockIntrinsicValueAmount
5.17
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.29
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
34.00
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6000000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4400000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4084000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
773000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Number Of Employees Affected
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
2
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.78
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.014
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
21000000
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2016Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2015Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5700000
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5000000

Files In Submission

Name View Source Status
0001564590-16-018295-index-headers.html Edgar Link pending
0001564590-16-018295-index.html Edgar Link pending
0001564590-16-018295.txt Edgar Link pending
0001564590-16-018295-xbrl.zip Edgar Link pending
aavl-10q_20160331.htm Edgar Link pending
aavl-20160331.xml Edgar Link completed
aavl-20160331.xsd Edgar Link pending
aavl-20160331_cal.xml Edgar Link unprocessable
aavl-20160331_def.xml Edgar Link unprocessable
aavl-20160331_lab.xml Edgar Link unprocessable
aavl-20160331_pre.xml Edgar Link unprocessable
aavl-ex311_22.htm Edgar Link pending
aavl-ex321_23.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending